Veru: The shift from the heavy cap-weighted names to a more broadening out of the market is underwy
Dan Veru of Palisade Capital Management discusses how a pickup in the broader market, outside of mega-cap tech and work-from…
Börse:
-100,00%
Echtzeit-Aktienkurs Veru Inc.
Bid:
Ask:
Nachrichten zur Veru Inc. Aktie
Veru Announces ESMO Congress 2020 Oral Presentation of Positive Clinical Results from its VERU-111 Phase 1b Study in Metastatic Prostate Cancer
—Advancing VERU-111 to a Pivotal Phase 3 Clinical Program—...…
Veru to Participate and Present at Four Upcoming Healthcare Investor Conferences
MIAMI, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company with…
Veru: The Russell 200 has emerged as the reopening benchmark
Dan Veru, co-chairman and chief investment officer at Palisade Capital Management, talks about markets amid a rally in equities, pointing…
Veru Inc. (VERU) Q3 2020 Earnings Call Transcript
VERU earnings call for the period ending June 30, 2020....…
VERU INC.: 10-Q Report
10-Q...…
Veru Inc. (VERU) CEO Mitchell Steiner on Q3 2020 Results - Earnings Call Transcript
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Veru: Q3 Earnings Insights
Shares of Veru (NASDAQ:VERU) rose 4% in pre-market trading after the company reported Q3 results.
Quarterly Results
Earnings per share decreased 25.00%…
Veru dips after missing FQ3 expectations
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Veru EPS misses by $0.02, misses on revenue
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Veru Reports Higher Net Revenues for Fiscal 2020 Third Quarter
--Received Agreement and Positive Input from FDA on Phase 3 Pivotal Clinical Trial Design for VERU-111; Phase 3 Trial Expected…
Veru Announces ESMO Congress 2020 Acceptance of VERU-111, a Novel Oral Tubulin Targeting Agent, Phase 1b/2 Study in Metastatic Prostate Cancer as an Oral Presentation
MIAMI, July 27, 2020 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company with…
Veru Receives Positive Input from FDA on Phase 3 Pivotal Trial to Evaluate VERU-111 in Metastatic Castration Resistant Prostate Cancer
--Pivotal Phase 3 Clinical Trial Expected to Initiate First Quarter Calendar Year 2021-- --Pivotal Phase 3 Clinical Trial Expected to…
Veru: Investors can have their cake and eat it too with convertible securities
Dan Veru of Palisade Capital Management says if investors have missed some of the market rally, they can still take…
Veru added to key indexes
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Veru Inc. Added to the Russell 2000 and 3000 Indices
MIAMI, June 29, 2020 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company with…
Veru (VERU) Soars: Stock Adds 6.9% in Session
Veru (VERU) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes....…
Veru Enrolls First Patient in Phase 2 Clinical Trial of Novel Drug, VERU-111, to Combat COVID-19
--VERU-111 has potential to treat both the SARS-CoV-2 virus infection and the severe inflammation leading to acute respiratory distress syndrome--…
Veru (VERU) Presents At Jefferies Virtual Healthcare Conference - Slideshow
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Veru to Present at Jefferies Virtual Healthcare Conference on June 2nd
MIAMI, May 26, 2020 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company with…
Veru Inc. (VERU) CEO Mitchell Steiner on Q2 2020 Results - Earnings Call Transcript
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Veru Inc. (VERU) Q2 2020 Earnings Call Transcript
VERU earnings call for the period ending March 31, 2020....…
Why Veru Stock Is Vaulting Higher Today
Investors liked the drugmakers positive Q1 update. And they liked its news about a COVID-19 clinical study even more....…
Veru Reports Strong Fiscal 2020 Second Quarter Results as Net Revenues Increase 43%, Gross Profit Up 61%
--Strong Clinical Progress in Advanced Prostate Cancer: VERU-111 Demonstrates Safety and Evidence of Antitumor Activity with Durable PSA Declines and…
Veru EPS beats by $0.02, misses on revenue
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Veru Reports Positive Clinical Results from VERU-111 Phase 1b/2 Trial in Men with Metastatic Castration-Resistant Prostate Cancer, Advancing to Pivotal Phase 3 Clinical Program
--VERU-111 Safe and Well Tolerated at Daily Doses 63 mg and Lower; No Significant Neutropenia…
Veru Inc. (VERU) CEO Mitchell Steiner on Q1 2020 Results - Earnings Call Transcript
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Veru Continues Strong Positive Sales Momentum in Fiscal 2020 First Quarter; Net Revenues Increase 66%, Gross Profit Up 57%
--Completion of VERU-111 Phase 1b Clinical Trial and Initiation of Phase 2 Prostate Cancer Clinical Trial in Q2 FY 2020--…
Veru EPS misses by $0.03, beats on revenue
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Palisades Veru on coronavirus: "I dont think its going to impair economies around the world"
Dan Veru, co-chairman and chief investment officer at Palisade Capital Management, on the economic implications of the coronavirus as the…
Veru Announces Acceptance of Two Abstracts for Presentation at the Genitourinary Cancer Symposium in February 2020
MIAMI , Jan. 21, 2020 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), The Prostate Cancer Company, an oncology…
Veru says drug reduces hot flashes in men in mid-stage study
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Verus experimental drug reduces hot flashes in men in mid-stage study
Veru Inc said on Monday a higher
dose of its experimental drug reduced hot flashes in men with
advanced prostate cancer after…
Veru Announces Positive Top-Line Interim Data from Phase 2 Clinical Trial of Zuclomiphene to Treat Hot Flashes in Men with Prostate Cancer on Androgen Deprivation Therapy
-- Plans to Advance Zuclomiphene into Pivotal Phase 3 Clinical Trial in First Half of 2020 -- -- Potential to…